Dr. Jing Wang 王晶
Chief Physician
Department of Medical Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of primary lung cancer.
Dr. Wang is a Chief Physician in the Department of Medical Oncology at Tianjin Medical University Cancer Institute & Hospital. Dr. Wang earned a bachelor's degree in clinical medicine (1989–1994) and a master's degree in oncology (2004–2007) from Tianjin Medical University. Prior to joining the hospital in 2007, Dr. Wang worked in general internal medicine and hematology at Tianjin Tianhe Hospital. Dr. Wang completed training in anti-cancer new drug clinical trials organized by the National Medical Products Administration.
Name order: in Chinese the family name comes first (Wang Jing). Papers usually list the name as Jing Wang or Wang J.
Selected publications
133 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Endocrinol (Lausanne), 2025 (senior author): Thoracic vertebral bone mineral density measured by quantitative computed tomography is associated with fracture risk in lung cancer screening populations: a prospective cohort study. PubMed 41323983
- Front Microbiol, 2025 (first author): Microbiome-metabolome dysbiosis of bronchoalveolar lavage fluid of lung cancer patients. PubMed 41311499
- Eur Radiol, 2025 (first author): Spectral CT-based nomogram for evaluation of neoadjuvant chemotherapy response in esophageal squamous cell carcinoma. PubMed 39729110
- J Thorac Dis, 2025 (first author): Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study. PubMed 40529739
- Anal Chem, 2025 (first author): A Smart DNA Network-Based Diagnostic System for Enrichment and Detection of Circulating Tumor Cells in Cancer Liquid Biopsy. PubMed 40185686
- Cancer Med, 2025 (first author): Risk Factors for Financial Toxicity in Patients With Pancreatic Cancer. PubMed 40251767
- Cell Death Dis, 2024 (first author): VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination. PubMed 39443476
- Exp Ther Med, 2024 (first author): Apatinib beyond first progression is associated with prolonged overall survival in patients with advanced breast cancer: Results from an observational study. PubMed 38590562
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion